Azevan Pharmaceuticals is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. The Companyís first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of Intermittent Explosive Disorder, neuropsychiatric symptoms in neurodegenerative diseases, PTSD, and other affective disorders. Vasopressin 1a receptor antagonists represent a novel mechanism of action for addressing these indications.
A 12 week Phase II Clinical Trial with SRX246 for the treatment of Intermittent Explosive Disorder launched in Q2 2014. Additional Phase II studies are planned in other indications.